Do arachidonic-acid mediators amplify neuroinflammatory signaling while EPA-derived mediators help resolve it?

In the CNS, inflammatory lipid signaling is not simply “pro-” versus “anti-inflammatory.” Activated microglia and astrocytes use arachidonic-acid (AA) metabolites in context-dependent circuits that can sustain neuroinflammation, while EPA-derived resolvins are an emerging potential counter-regulatory pathway.

AA-derived inflammatory signaling

• Activated microglia release AA through phospholipase A₂ and metabolize it via COX-2 and 5-lipoxygenase to prostaglandins and leukotrienes, including PGE₂ and LTB₄. Activated astrocytes similarly use cPLA₂-dependent AA release and generate prostaglandins and leukotriene-related oxylipins.
• PGE₂—particularly through EP2 receptors—can engage cAMP/PKA, NOX2, NF-κB, oxidative-stress, and cytokine-transcription pathways. LTB₄ promotes chemotaxis and inflammatory signaling. These signals may form feed-forward microglia–astrocyte activation loops that worsen neuronal injury.
• Human postmortem Alzheimer disease findings are consistent with this framework: PGE₂-related lipids, LTB₄, and several HETEs are elevated, while the pro-resolving mediator lipoxin A₄ is reduced. However, AA metabolites are not uniformly harmful; lipoxins can constrain glial reactivity.

EPA-derived resolution mechanisms

• The best direct evidence concerns resolvin E1 (RvE1), an EPA-derived specialized pro-resolving mediator. In cell and rodent models, RvE1 reduced lipopolysaccharide-induced microglial activation and TNF-α, IL-1β, and IL-6 release, with NF-κB inhibition implicated.
• Intrathecal RvE1 reduced microglial inflammatory signaling and mechanical allodynia in a rodent chronic-constriction-injury model. Candidate mechanisms include ChemR23/CMKLR1 signaling and functional opposition of BLT1, potentially supporting phagocytosis and clearance processes.

Bottom line

• AA-derived PGE₂- and leukotriene-associated pathways are well-supported contributors to amplification of glial neuroinflammatory signaling. EPA-derived RvE1 plausibly counteracts this activity preclinically, but evidence that EPA-derived mediators broadly—and in humans—terminate CNS inflammation remains preliminary.